Smartleaf Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$669 Buy
57
+20
+54% +$343 ﹤0.01% 3284
2026
Q2
$884 Hold
37
– – ﹤0.01% 3119
2026
Q1
$575 Hold
37
– – ﹤0.01% 3203
2025
Q4
$591 Buy
+37
New +$499 ﹤0.01% 3245

Other funds holding GLUE

Smartleaf Asset Management's GLUE Position: Q3 2026 in Review

Smartleaf Asset Management increased its Monte Rosa Therapeutics (GLUE) stake by 54% in Q3 2026, buying an estimated $343 and bringing the position to 57 shares worth $669. The position accounts for ﹤0.01% of the portfolio, ranked #3284.

Smartleaf Asset Management first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $884 in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Smartleaf Asset Management held 57 shares of Monte Rosa Therapeutics worth $669 as of Q3 2026.
  • Smartleaf Asset Management bought 20 Monte Rosa Therapeutics shares in Q3 2026, an estimated $343.
  • Monte Rosa Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3284 holding.
  • Smartleaf Asset Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Smartleaf Asset Management's Monte Rosa Therapeutics position peaked at $884 in Q2 2026.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.